Short Interest in ZyVersa Therapeutics, Inc. (NASDAQ:ZVSA) Decreases By 46.0%

ZyVersa Therapeutics, Inc. (NASDAQ:ZVSA) saw a large decrease in short interest in the month of June. As of June 30th, there was short interest totalling 18,900 shares, a decrease of 46.0% from the June 15th total of 35,000 shares. Currently, 2.3% of the shares of the company are sold short. Based on an average trading volume of 263,900 shares, the days-to-cover ratio is presently 0.1 days.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reissued a “buy” rating and set a $120.00 price objective on shares of ZyVersa Therapeutics in a report on Tuesday, March 26th.

ZyVersa Therapeutics Stock Performance

Shares of NASDAQ ZVSA opened at $4.90 on Friday. ZyVersa Therapeutics has a 52 week low of $3.41 and a 52 week high of $90.65. The business has a 50-day simple moving average of $4.61 and a two-hundred day simple moving average of $6.35.

ZyVersa Therapeutics (NASDAQ:ZVSA) last issued its earnings results on Wednesday, May 15th. The company reported ($4.53) EPS for the quarter, missing the consensus estimate of ($3.70) by ($0.83). On average, equities research analysts expect that ZyVersa Therapeutics will post -15.05 EPS for the current fiscal year.

About ZyVersa Therapeutics

ZyVersa Therapeutics, Inc, a clinical stage biopharmaceutical company, develops and commercializes products for the treatment of renal and inflammatory diseases. The company develops drug development platforms, including Cholesterol Efflux Mediator VAR 200, an injectable drug, which is in Phase 2a clinical trial to the treatment of renal indications, such as focal segmental glomerulosclerosis, alport syndrome, and diabetic kidney diseases; and Inflammasome ASC Inhibitor IC 100, a humanized monoclonal antibody that is in preclinical stage for treatment of inflammatory diseases comprising acute respiratory syndrome, multiple sclerosis, IgA neuropathy, pancreatic cancer, Parkinson's and Huntington's disease, atherosclerosis, Alzheimer's disease, and obesity.